Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E, Terrazas C, Satoskar AR, Gunes EG, Dona A, Sanchez JF, Bergsagel PL, Chesi M, Pozhitkov A, Rosen S, Marcucci G, Keats JJ, Hofmeister CC, Krishnan A, Caserta E, Pichiorri F.

JCI Insight. 2019 Nov 1;4(21). pii: 129348. doi: 10.1172/jci.insight.129348.

2.

Identification of PIKfyve kinase as a target in multiple myeloma.

Bonolo De Campos C, Zhu YX, Sepetov N, Romanov S, Bruins LA, Shi CX, Stein CK, Petit JL, Polito AN, Sharik ME, Meermeier EW, Ahmann GJ, Lopez Armenta ID, Kruse J, Bergsagel PL, Chesi M, Meurice N, Braggio E, Stewart AK.

Haematologica. 2019 Oct 3. pii: haematol.2019.222729. doi: 10.3324/haematol.2019.222729. [Epub ahead of print]

3.

MYC dysregulation in the progression of multiple myeloma.

Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortüm KM, Keats JJ; MMRF CoMMpass Network, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL.

Leukemia. 2020 Jan;34(1):322-326. doi: 10.1038/s41375-019-0543-4. Epub 2019 Aug 22. No abstract available.

PMID:
31439946
4.

Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.

Akhmetzyanova I, McCarron MJ, Parekh S, Chesi M, Bergsagel PL, Fooksman DR.

Leukemia. 2020 Jan;34(1):245-256. doi: 10.1038/s41375-019-0519-4. Epub 2019 Aug 22.

PMID:
31439945
5.

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Guillerey C, Nakamura K, Pichler AC, Barkauskas D, Krumeich S, Stannard K, Miles K, Harjunpää H, Yu Y, Casey M, Doban AI, Lazar M, Hartel G, Smith D, Vuckovic S, Teng MW, Bergsagel PL, Chesi M, Hill GR, Martinet L, Smyth MJ.

JCI Insight. 2019 Jun 13;5. pii: 125932. doi: 10.1172/jci.insight.125932.

6.

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.

Thirukkumaran CM, Shi ZQ, Nuovo GJ, Luider J, Kopciuk KA, Dong Y, Mostafa AA, Thakur S, Gratton K, Yang A, Chin AC, Coffey MC, Jimenez-Zepeda VH, Stewart D, Chesi M, Bergsagel PL, Morris D.

Blood Adv. 2019 Mar 12;3(5):797-812. doi: 10.1182/bloodadvances.2018025593.

7.

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M.

Nat Commun. 2018 Dec 3;9(1):4832. doi: 10.1038/s41467-018-07305-8.

8.

Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.

Robinson RM, Reyes L, Duncan RM, Bian H, Reitz AB, Manevich Y, McClure JJ, Champion MM, Chou CJ, Sharik ME, Chesi M, Bergsagel PL, Dolloff NG.

Leukemia. 2019 Apr;33(4):1011-1022. doi: 10.1038/s41375-018-0263-1. Epub 2018 Oct 12.

PMID:
30315229
9.

Bone marrow transplantation generates T cell-dependent control of myeloma in mice.

Vuckovic S, Minnie SA, Smith D, Gartlan KH, Watkins TS, Markey KA, Mukhopadhyay P, Guillerey C, Kuns RD, Locke KR, Pritchard AL, Johansson PA, Varelias A, Zhang P, Huntington ND, Waddell N, Chesi M, Miles JJ, Smyth MJ, Hill GR.

J Clin Invest. 2019 Jan 2;129(1):106-121. doi: 10.1172/JCI98888. Epub 2018 Nov 19.

10.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.

JCI Insight. 2018 Apr 19;3(8). pii: 98259. doi: 10.1172/jci.insight.98259. eCollection 2018 Apr 19.

11.

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM.

J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.

12.

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ.

Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007.

13.

Importin-β and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells.

Nuovo G, Tran H, Gutierrez A, Fadda P, Pichiorri F, Caserta E, Hofmeister CC, Chesi M, Leif Bergsagel P, Morris D, Shi Q, Coffey M, Thirukkumaran C.

Ann Diagn Pathol. 2018 Feb;32:28-34. doi: 10.1016/j.anndiagpath.2017.10.001. Epub 2017 Oct 7.

PMID:
29414394
14.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.

Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG 3rd, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M.

Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6.

15.

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM.

J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y.

16.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

17.

Antibodies Create Killer Bonds in Myeloma.

Chesi M, Fonseca R.

Cancer Cell. 2017 Mar 13;31(3):305-307. doi: 10.1016/j.ccell.2017.02.011.

18.

Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R.

Blood. 2017 Feb 23;129(8):991-1007. doi: 10.1182/blood-2016-09-738872. Epub 2016 Dec 27.

19.

Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.

Bordini J, Galvan S, Ponzoni M, Bertilaccio MT, Chesi M, Bergsagel PL, Camaschella C, Campanella A.

Leukemia. 2017 Apr;31(4):967-970. doi: 10.1038/leu.2016.346. Epub 2016 Nov 24. No abstract available.

PMID:
27881873
20.

IAP antagonists induce anti-tumor immunity in multiple myeloma.

Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL.

Nat Med. 2016 Dec;22(12):1411-1420. doi: 10.1038/nm.4229. Epub 2016 Nov 14.

21.

Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma.

Jain T, Dueck AC, Kosiorek HE, Ginos BF, Mayo A, Reeder CB, Chesi M, Mikhael J, Keith Stewart A, Leif Bergsagel P, Fonseca R.

Am J Hematol. 2016 Dec;91(12):E504-E505. doi: 10.1002/ajh.24548. Epub 2016 Oct 11. No abstract available.

22.

Promiscuous mechanisms underlie the antitumor effects of thalidomide analogs.

Bergsagel PL, Chesi M.

Nat Med. 2016 Jul 7;22(7):706-7. doi: 10.1038/nm.4144. No abstract available.

PMID:
27387882
23.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

24.

Targeting vasculogenesis to prevent progression in multiple myeloma.

Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM.

Leukemia. 2016 May;30(5):1103-15. doi: 10.1038/leu.2016.3. Epub 2016 Feb 3.

PMID:
26859080
25.

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.

Hussain S, Bedekovics T, Chesi M, Bergsagel PL, Galardy PJ.

Oncotarget. 2015 Dec 1;6(38):40704-18. doi: 10.18632/oncotarget.5727.

26.

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu S.

Nat Commun. 2015 Oct 12;6:8428. doi: 10.1038/ncomms9428.

PMID:
26455434
27.

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.

Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Sabrina Bertilaccio MT, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A, Bellone M.

Oncoimmunology. 2015 May 7;4(6):e1008850. eCollection 2015 Jun.

28.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 Jul 1;125(7):2904. doi: 10.1172/JCI82646. Epub 2015 Jun 15. No abstract available.

29.

Advances in the pathogenesis and diagnosis of multiple myeloma.

Chesi M, Bergsagel PL.

Int J Lab Hematol. 2015 May;37 Suppl 1:108-14. doi: 10.1111/ijlh.12360. Review.

PMID:
25976968
30.

Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F.

Cancer Immunol Res. 2015 Aug;3(8):881-90. doi: 10.1158/2326-6066.CIR-15-0025-T. Epub 2015 May 4.

31.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 May;125(5):2077-89. doi: 10.1172/JCI77181. Epub 2015 Apr 20. Erratum in: J Clin Invest. 2015 Jul 1;125(7):2904. Chesi, Martha [corrected to Chesi, Marta].

32.

Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.

Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, Bossi G, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, Blandino G, Fanciulli M.

EMBO J. 2015 May 5;34(9):1214-30. doi: 10.15252/embj.201489920. Epub 2015 Mar 14.

33.

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.

Bordini J, Bertilaccio MT, Ponzoni M, Fermo I, Chesi M, Bergsagel PL, Camaschella C, Campanella A.

Haematologica. 2015 Jun;100(6):834-841. doi: 10.3324/haematol.2014.118000. Epub 2015 Feb 24.

34.

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.

Westwood JA, Matthews GM, Shortt J, Faulkner D, Pegram HJ, Duong CP, Chesi M, Bergsagel PL, Sharp LL, Huhn RD, Darcy PK, Johnstone RW, Kershaw MH.

Leuk Res. 2014 Aug;38(8):948-54. doi: 10.1016/j.leukres.2014.05.010. Epub 2014 Jun 2.

PMID:
24934848
35.

The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.

Shortt J, Hsu AK, Martin BP, Doggett K, Matthews GM, Doyle MA, Ellul J, Jockel TE, Andrews DM, Hogg SJ, Reitsma A, Faulkner D, Bergsagel PL, Chesi M, Heath JK, Denny WA, Thompson PE, Neeson PJ, Ritchie DS, McArthur GA, Johnstone RW.

Cell Rep. 2014 May 22;7(4):1009-19. doi: 10.1016/j.celrep.2014.04.008. Epub 2014 May 9.

36.

CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D, Utley A, Chesi M, Bergsagel PL, Boise LH, Lee KP.

Blood. 2014 Jun 12;123(24):3770-9. doi: 10.1182/blood-2013-10-530964. Epub 2014 Apr 29.

37.

TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F.

Blood. 2014 May 22;123(21):3305-15. doi: 10.1182/blood-2014-02-554071. Epub 2014 Apr 10.

38.

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, Van Wier S, Fonseca R, Bergsagel PL, Kuehl WM.

Leukemia. 2014 Aug;28(8):1725-1735. doi: 10.1038/leu.2014.70. Epub 2014 Feb 12.

39.

A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union.

Grover RK, Zhu X, Nieusma T, Jones T, Boreo I, MacLeod AS, Mark A, Niessen S, Kim HJ, Kong L, Assad-Garcia N, Kwon K, Chesi M, Smider VV, Salomon DR, Jelinek DF, Kyle RA, Pyles RB, Glass JI, Ward AB, Wilson IA, Lerner RA.

Science. 2014 Feb 7;343(6171):656-661. doi: 10.1126/science.1246135.

40.

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.

Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W.

Blood. 2014 Jan 30;123(5):725-33. doi: 10.1182/blood-2013-08-524025. Epub 2013 Dec 17.

41.

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

Matthews GM, Lefebure M, Doyle MA, Shortt J, Ellul J, Chesi M, Banks KM, Vidacs E, Faulkner D, Atadja P, Bergsagel PL, Johnstone RW.

Cell Death Dis. 2013 Sep 12;4:e798. doi: 10.1038/cddis.2013.306.

42.

V. Molecular classification and risk stratification of myeloma.

Bergsagel PL, Chesi M.

Hematol Oncol. 2013 Jun;31 Suppl 1:38-41. doi: 10.1002/hon.2065. Review. No abstract available.

43.

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK.

Leukemia. 2013 Dec;27(12):2357-65. doi: 10.1038/leu.2013.172. Epub 2013 Jun 11.

44.

Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Chesi M, Bergsagel PL.

Int J Hematol. 2013 Mar;97(3):313-23. doi: 10.1007/s12185-013-1291-2. Epub 2013 Feb 28. Review.

45.

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.

Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A.

Oncogene. 2014 Jan 16;33(3):316-25. doi: 10.1038/onc.2012.594. Epub 2013 Jan 14.

PMID:
23318440
46.

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, Bots M, Zuber J, Lowe SW, Johnstone RW, Smyth MJ.

Blood. 2012 Oct 11;120(15):3019-29. doi: 10.1182/blood-2012-04-426643. Epub 2012 Aug 28.

47.

Clonal competition with alternating dominance in multiple myeloma.

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL.

Blood. 2012 Aug 2;120(5):1067-76. doi: 10.1182/blood-2012-01-405985. Epub 2012 Apr 12.

48.

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL.

Blood. 2012 Jul 12;120(2):376-85. doi: 10.1182/blood-2012-02-412783. Epub 2012 Mar 26.

49.

Many multiple myelomas: making more of the molecular mayhem.

Chesi M, Bergsagel PL.

Hematology Am Soc Hematol Educ Program. 2011;2011:344-53. doi: 10.1182/asheducation-2011.1.344. Review.

50.

Role of Pirh2 in mediating the regulation of p53 and c-Myc.

Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, Madore J, Boutros P, Sheng Y, Chesi M, Bergsagel PL, Perez-Ordonez B, Mes-Masson AM, Penn L, Squire J, Chen X, Jurisica I, Arrowsmith C, Sanchez O, Benchimol S, Hakem R.

PLoS Genet. 2011 Nov;7(11):e1002360. doi: 10.1371/journal.pgen.1002360. Epub 2011 Nov 17.

Supplemental Content

Support Center